Pascal Soriot is still hard at work in patching up AstraZeneca's (NYSE:AZN) battered pipeline and five-year profit prospects. Following the announcement of an agreement to acquire Omthera (Nasdaq:OMTH)
to boost the company's cardiovascular drug business, AstraZeneca
announced Monday that it was acquiring development-stage COPD drug
developer Pearl Therapeutics. While AstraZeneca does not appear to be
buying a future blockbuster, the deal should be a relatively low-risk
way to boost the company's important respiratory drug franchise and
offset some of the downside risk to the five-year revenue and profit
outlook.
Please continue reading here:
http://www.investopedia.com/stock-analysis/061013/astrazeneca-pays-patch-another-key-area-azn-gsk-thrx-nvs-frx.aspx
No comments:
Post a Comment